Syndax Pharmaceuticals (SNDX) Return on Capital Employed (2016 - 2026)

Syndax Pharmaceuticals' Return on Capital Employed history runs 11 years deep, the most recent figure standing at 53.86% for Q1 2026.

• On a quarterly basis, Return on Capital Employed rose 461.0% year-over-year to 53.86% in Q1 2026; TTM through Mar 2026 was 53.86%, a 461.0% increase from a year earlier, with the FY2025 full-year figure at 53.85%, up 624.0% from the prior year.
• Return on Capital Employed improved to 53.86% in Q1 2026 per SNDX's latest filing, from 64.92% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 4.08% in Q1 2022 and bottomed at 81.94% in Q3 2024.
• The 5-year median for Return on Capital Employed is 51.6% (2023), against an average of 46.71%.
• Across the five-year window, Return on Capital Employed jumped 3640 bps in 2022 and tumbled 4775 bps in 2023, its largest moves.
• Year by year, Return on Capital Employed stood at 38.0% in 2022, then plunged by 35 bps to 51.33% in 2023, then plunged by 40 bps to 72.0% in 2024, then increased by 10 bps to 64.92% in 2025, then gained by 17 bps to 53.86% in 2026.
• Per Business Quant, the three latest SNDX Return on Capital Employed figures stand at 53.86% (Q1 2026), 64.92% (Q4 2025), and 66.75% (Q3 2025).